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SUMMARY
PBRM1 is the second most commonly mutated gene
after VHL in clear cell renal cell carcinoma (ccRCC).
However, the biological consequences of PBRM1
mutations for kidney tumorigenesis are unknown.
Here, we find that kidney-specific deletion of Vhl
and Pbrm1, but not either gene alone, results in
bilateral, multifocal, transplantable clear cell kidney
cancers. PBRM1 loss amplified the transcriptional
outputsofHIF1andSTAT3 incurredbyVhldeficiency.
Analysis of mouse and human ccRCC revealed
convergence on mTOR activation, representing the
third driver event after genetic inactivation of VHL
and PBRM1. Our study reports a physiological
preclinical ccRCC mouse model that recapitulates
somatic mutations in human ccRCC and provides
mechanistic and therapeutic insights into PBRM1
mutated subtypes of human ccRCC.
INTRODUCTION
The estimated new kidney cancer cases diagnosed in the world
and the United Sates every year are 300,000 and 63,000,
respectively (Fitzmaurice et al., 2015; Siegel et al., 2016). Clear
cell renal cell carcinoma (ccRCC) is the most common subtype
(75%) (Hsieh et al., 2017b) and is lethal when metastasized
(Rini et al., 2009). TheVonHippel-Lindau (VHL) tumor suppressor
gene is the most frequently mutated gene in ccRCC (Gnarra
et al., 1994; Linehan et al., 1995) and its complete loss consti-
tutes an early, truncal oncogenic driver event. VHL is the sub-
strate recognition of an E3 ligase that labels hypoxia-inducible
factor (HIF) 1a and 2a with ubiquitin for degradation (Kaelin,
2007; Majmundar et al., 2010; Masson and Ratcliffe, 2014; Se-
menza, 2013). Thus, human ccRCC is highly vascular due to un-
controlled activation of HIFa targets that regulate angiogenesis.
Thereby, anti-vascular endothelial growth factor (VEGF)/
vascular endothelial growth factor receptor (VEGFR) agents are
effective, first-line treatment for metastatic ccRCC (mRCC)
(Rini et al., 2009; Voss et al., 2013).
VHL inactivation was the only known oncogenic driver
in ccRCC (Gnarra et al., 1994) until recent large-scale cancer
genomic projects uncovered prevalent mutations including
PBRM1/BAF180 (29%–41%), SETD2 (8%–12%), BAP1 (6%–
10%), and KDM5C (4%–7%) (Cancer Genome Atlas Research
Network, 2013; Hakimi et al., 2013a; Pen˜a-Llopis et al.,
2012; Sato et al., 2013; Varela et al., 2011). Remarkably, these
genes encode chromatin and epigenetic regulatory proteins,
and most mutations are predicted to result in functional loss,
favoring their roles as tumor suppressors (Hakimi et al.,
2013b). PBRM1, the second most commonly mutated gene in
all stages of ccRCC (Hsieh et al., 2017a), encodes BRG1-asso-
ciated factor (BAF) 180, the defining subunit of the 2 million
dalton (MDa) polybromo BAF (PBAF) SWI/SNF complex (Varela
et al., 2011). The SWI/SNF chromatin remodeling complexes
are macromolecular machineries, which utilize ATP to mobilize
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nucleosome and thereby modulate chromatin structure (Biegel
et al., 2014; Clapier and Cairns, 2009). They regulate critical
cellular processes, including cell-cycle, cell fate, cell death,
metabolism, and DNA repair (Hargreaves and Crabtree, 2011).
Interestingly, pan-cancer genomics have uncovered epigenetic
regulators including SWI/SNF proteins as amajor class of cancer
genes (Dawson and Kouzarides, 2012). Mutations of individual
SWI/SNF subunits have been detected in 20% of human can-
cers and they displayed preferential enrichment of mutations
among cancer types (Helming et al., 2014; Kadoch et al., 2013;
Marquez et al., 2015). For example, PBRM1 is most highly
mutated in ccRCC, SMARCB1 (BAF47) in pediatric rhabdoid
tumors and ARID1A (BAF250A) in ovarian clear cell carcinoma
(Biegel et al., 2014), implicating underlying tissue tropism for
disarming specific tumor suppressor gene (TSG) during tumori-
genesis (Wei and Hsieh, 2015).
The knowledge of PBRM1 in mammalian biology is limited.
Mice with straight knockout of Pbrm1 resulted in embryonic
lethality at embryonic day 11.5 due to heart defects (Huang
et al., 2008; Wang et al., 2004), whereas mice with T lympho-
cyte-specific knockout of Pbrm1 exhibited normal thymus and
peripheral T cell development (Wurster et al., 2012). In vitro
studies demonstrated that PBRM1 activated p21 upon irradia-
tion in breast cancer cell lines (Xia et al., 2008) and participated
in p53-induced replicative senescence in fibroblasts (Burrows
et al., 2010), and PBRM1 knockdown enhanced proliferation
and migration of kidney cancer cell lines (Varela et al., 2011).
However, the in vivo tumor suppressor function of PBRM1 has
not been established, and how PBRM1 loss-of-function pro-
motes tumorigenesis remains unclear.
The long latency (>30 years) for VHL germline-mutated pa-
tients to develop ccRCC (Fisher et al., 2014; Kaelin, 2007) and
the inability of Vhl deficiency to induce ccRCC in mice (Kapitsi-
nou and Haase, 2008) suggest that additional genetic/epigenetic
events are probably needed for the development of ccRCC (Wei
and Hsieh, 2015). PBRM1 loss-of-function is one of the most
likely candidates given its high mutation frequency (40%) in
humanccRCC (Hsiehet al., 2017a).Here,wecreatedkidney-spe-
cific deletion of Pbrm1 and/or Vhl mice to study the tumor sup-
pressor role of PBRM1 and sought to establish a physiological
mouse kidney cancer model that recapitulates human ccRCC.
RESULTS
Genetic Deletion of Pbrm1 in Mouse Kidney Results in
Hydronephrosis
As Pbrm1 (BAF180) deletion in mice incurred embryonic lethality
(Wang et al., 2004), we deleted the conditional Pbrm1F allele
(Wurster et al., 2012) in the mouse kidney using a transgenic
Cre recombinase line Ksp-Cre (Shao et al., 2002) that has been
widely utilized to model kidney cancer in mice (Adam et al.,
2011; Baba et al., 2008; Chen et al., 2008; Igarashi, 2004). The
expression of Cre from the Ksp-Cre is driven by the kidney-spe-
cific Cadherin 16 promoter, which begins expression at embry-
onic day 14.5 in epithelial cells of the developing kidney and
genitourinary tract and continues to be expressed in tubular
epithelial cells in adults. Pbrm1F/FKsp-Cremice were born at ex-
pected Mendelian ratio. To monitor if Pbrm1 loss results in any
gross kidney abnormality, serial abdominal MRI was performed
on a large cohort of mice. Obstructive hydronephrosis, enlarged
kidneys containing fluid-filled renal pelvis, and non-neoplastic
masses at the ureteropelvic junction or proximal ureter were de-
tected in some Pbrm1F/FKsp-Cre mice (Figures 1A and S1A).
Among 53 Pbrm1F/FKsp-Cre and 27 Pbrm1+/+Ksp-Cre (denoted
as WT thereafter) mice examined, 18 (34%) Pbrm1F/FKsp-Cre
while 0 WT mice developed hydronephrosis (Figure 1B).
Observed hydronephrosis exhibited a preponderance of female
over male and left over right (Figures 1C and 1D) and could be
detected by MRI as early as 6 months of age (Figure S1B). At
necropsy, the volume of hydronephrotic Pbrm1F/FKsp-Cre kid-
neys was at two to five times that of normal appearing kidneys
(Figure 1E), whereas the creatinine of aged Pbrm1F/FKsp-Cre
and WT mice was comparable (Figure 1F).
Genetic Deletion of Vhl and Pbrm1 in Mouse Kidney
Results in Polycystic Kidney Disease and Increased
Mortality
As neither Vhl nor Pbrm1 deletion alone caused kidney tumors,
VhlF/FPbrm1F/FKsp-Cre mice were generated to investigate the
genetic interaction between Vhl and Pbrm1 deficiency in kidney
cancer pathogenesis. The survival of 325 mice (36 WT, 30 VhlF/F
Ksp-Cre, 129 Pbrm1F/FKsp-Cre, and 130 VhlF/FPbrm1F/FKsp-
Cre) was monitored, which revealed a markedly increased mor-
tality in VhlF/FPbrm1F/FKsp-Cremice and a moderately increased
mortality in VhlF/FKsp-Cremice (Figure 2A). Remarkably, abdom-
inal MRI detected diffuse polycystic kidney disease (PKD) in
30% (17/56) of 6- to 9-month-old and in 67% (14/21) of 10- to
14-month-old VhlF/FPbrm1F/FKsp-Cremice, whereas only 1 of 14
aged VhlF/FKsp-Cre mice (12- to 16-month-old) developed PKD
with a few scattered cysts (Figures 2B, 2C, and S2). To investigate
cystic changes, weperformed histological analysis on the kidneys
of VhlF/FPbrm1F/FKsp-Cre mice at different ages (3–13 months).
Both tubularandglomerularcystswerepresent inyoungmice (Fig-
ure S3). Of note, scattered cystic anomalies of kidneys have been
described in hereditary VHL patients and are implicated as pre-
neoplastic lesions (Mandriota et al., 2002; Neumann and Zbar,
1997; Walther et al., 1995). Consistent with a prior report, mild hy-
dronephrosiswas alsoobserved inVhlF/FKsp-Cremice (Figure2D)
(Frew et al., 2008). Elevated serum creatinine was observed in the
majority of aged VhlF/FPbrm1F/FKsp-Cre mice (Figure 2E), which
could be accountable for their early demise.
VhlF/FPbrm1F/FKsp-Cre Mice Develop Multifocal, Clear
Cell Kidney Cancer
Serial MRI examination of kidney in VhlF/FPbrm1F/FKsp-Cremice
recognized patterns of imaging changes from normal through
progressive cystic abnormality to increasedmultifocal nodularity
with decreased cystic appearance (Figures S2 and S3). Gross
examination of 58 kidneys (29 mice, 8- to 17-month-old) at
necropsy showed diffusely cystic changes in 58.33% (21/36)
of VhlF/FPbrm1F/FKsp-Cre kidneys and none in VhlF/FKsp-Cre
(n = 8), Pbrm1F/FKsp-Cre (n = 10), andWT (n = 4) kidneys (Table
S1). Histologic examination revealed sheets of tumor cells inter-
spersed within a highly vascularized stroma in 33.33% (12/36)
VhlF/FPbrm1F/FKsp-Cre kidneys, whereas no tumors were noted
in 22 kidneys of the other genotypes (Table S1). Notably, all the
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tumors were observed in VhlF/FPbrm1F/FKsp-Cre mice after
10months of age with a 50% tumor incidence (12/24). The tumor
cells displayed central features of human ccRCC, including
clear cytoplasm and positive membranous staining of carbonic
anhydrase IX (CA-IX), a target of HIF1 (Mandriota et al., 2002;
Semenza, 2013) (Figure 3A). Consistent with the known aberrant
HIF1 activation in the absence of VHL, weak, sporadic CA-IX
staining was detected in VhlF/FKsp-Cre, but not in Pbrm1F/F
Ksp-Cre or WT kidneys (Figure 3A). To compare these mouse
tumorswith humanRCCs, we performed gene expression profile
analysis of these mouse tumors in comparison to human TCGA
clear cell RCC (KIRC) and chromophobe RCC (KICH) kidney
cancers and demonstrated that VhlF/FPbrm1F/FKsp-Cre tumors
resemble KIRC but not KICH (Figure 3B). Data suggest that
human clear cell RCC arises from proximal tubule (Chen
et al., 2016). Accordingly, we investigated the cell type origin of
VhlF/FPbrm1F/FKsp-Cre mouse tumors. Staining for lotus tetra-
gonolobus lectin (LTL) that marks proximal convoluted tubule
and for Tamm-Horsfall protein (THP) that marks distal convo-
luted tubule was performed. Consistent with human ccRCC orig-
inating from proximal tubule, our VhlF/FPbrm1F/FKsp-Cremouse
tumors were stained positive for LTL but not THP (Figure 3C).
CD45 staining did not detect increased lymphocyte infiltrate of
these VhlF/FPbrm1F/FKsp-Cre tumors (Figure 3C). Consistent
with human ccRCC reports, these tumors were positive for
CD31 staining that marks endothelial cells (Figure 3C). We also
performed Oil Red O staining of the fresh frozen section of these
mouse tumors to evaluate lipid content in our the clear cell
mouse tumors (Figure S4). Furthermore, the presence of high
glycogen in these tumors was confirmed by PAS-D staining (Fig-
ure S4). Of note, our VhlF/FPbrm1F/FKsp-Cre mouse tumors did
not directly originate from cystic lesions (Figure S5A). Higher
proliferation index (Ki-67 staining) was observed in these Vhl
and Pbrm1 doubly deficient clear cell kidney tumors whereas
no alteration in cell death was detected by immunohistochem-
istry for cleaved caspase-3 and TUNEL assays (Figures S5B
Figure 1. Pbrm1F/FKsp-Cre Mice Develop Obstructive Hydronephrosis
(A) Representative MRI images of unilateral or bilateral severe hydronephrosis. The non-neoplastic mass at the proximal ureter is marked by arrow.
(B) Incidence of hydronephrosis in WT and Pbrm1F/FKsp-Cremice. Cohorts of animals at 12months of age on average were randomly selected for MRI scanning.
***p < 0.001 (Fischer’s exact).
(C) Incidence of hydronephrosis in the Pbrm1F/FKsp-Cre mice based on gender.
(D) Location distribution of hydronephrosis in Pbrm1F/FKsp-Cre mouse kidneys.
(E) Kidney volume in WT and Pbrm1F/FKsp-Cre mice. *p < 0.05 (Mann-Whitney).
(F) Serum creatinine levels of mice in (E). ns, not statistically significant.
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and S5C). qPCR with reverse transcription (qRT-PCR) demon-
strated greatly reduced Vhl and Pbrm1 expression in VhlF/F
Pbrm1F/FKsp-Cre kidney tumors (Figure S5D). Of note, we did
not detect local tumor invasion into adjacent tissues or distant
metastasis to lungs, livers, bones, and lymph nodes in the exam-
ined tumor-bearing VhlF/FPbrm1F/FKsp-Cre mice.
Figure 2. VhlF/FPbrm1F/FKsp-Cre Mice Develop Polycystic Kidney Disease and Exhibit Premature Mortality
(A) Kaplan-Meier survival curve of WT, VhlF/FKsp-Cre, Pbrm1F/FKsp-Cre, and VhlF/FPbrm1F/FKsp-Cre mice.
(B) Incidence of polycystic kidney disease in WT, VhlF/FKsp-Cre, Pbrm1F/FKsp-Cre, and VhlF/FPbrm1F/FKsp-Cre. Age and number of animals in each group are
specified.
(C) Representative MRI and gross images of kidneys of the indicated genotypes.
(D) Kidney volumes of WT, VhlF/FKsp-Cre, and VhlF/FPbrm1F/FKsp-Cremice. Numbers of kidneys measured in each group (n) are indicated. **p = 0.0096; ***p <
0.0001 (Mann-Whitney).
(E) Serum creatinine levels in WT, VhlF/FKsp-Cre, and VhlF/FPbrm1F/FKsp-Cre mice (the same as Figure 1D). ***p < 0.001 (Mann-Whitney).
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Vhl and Pbrm1 Doubly Deficient Clear Cell Kidney
Tumors Are Transplantable
To assess the tumor initiating capacity of the de novo Vhl and
Pbrm1 doubly deficient kidney tumors, we transplanted 12 tumor
fragments from two VhlF/FPbrm1F/FKsp-Cre kidneys into the sub-
renal capsules of 12 kidneys of 6 immunocompromised NOD/
SCID/IL2Rgnull (NSG) mice. All the recipient kidneys, except for
the one animal that died prematurely of known cause, showed
large visible kidney tumors upon dissection at 10–12months after
transplantation (Figure 4A). In two of the transplanted cases, we
also observed tumor invasion into organs such as liver (Figure 4B).
Figure 3. VhlF/FPbrm1F/FKsp-Cre Mice
Develop Multifocal CA-IX Positive Clear
Cell Kidney Cancers
(A) Representative gross images (column 1),
histopathological images (column 2), and immu-
nohistochemistry of CA-IX (columns 3 and 4)
of WT, VhlF/FKsp-Cre, Pbrm1F/FKsp-Cre, and
VhlF/FPbrm1F/FKsp-Cre kidneys. Tumor and cyst
are indicated by white and black arrows, respec-
tively. T, tumor; N, adjacent normal. Scale bars are
at 50 mm, 100 mm, or 200 mm as indicated.
(B) Heatmap of inter-sample correlations (red,
positive) between mRNA profiles of TCGA human
RCC tumors (columns, TCGAKIRC andKICH data)
and VhlF/FPbrm1F/FKsp-Cre mouse kidney tumors
(rows).
(C) Representative images of immunofluorescence
of LTL (column 1) and immunohistochemistry of
THP (column 2), CD45 (column 3), and CD31 (col-
umn 4) in VhlF/FPbrm1F/FKsp-Cre tumors and
adjacent non-tumor tissues.
Furthermore, tumors that developed in
the transplanted NSG mouse could be
further successfully propagated into a
NSG mouse (Figure 4A). Together, these
data demonstrated the malignant poten-
tial of VhlF/FPbrm1F/FKsp-Cre kidney tu-
mors. Histology of these tumor allografts
showed the same histological features,
positive CA-IX staining as donor tumors,
and genotypes (Figure 4). Importantly,
this stepwise, morphological progression
observed in VhlF/FPbrm1F/FKsp-Cre kid-
neys from normal appearance through
cystic changes (6 months) to ccRCC for-
mation (10months)offeredanopportunity
to temporally dissect the mechanisms by
which PBRM1 loss cooperates with VHL
loss to initiate the development of ccRCC.
Gene Expression Profiling ofWT,
Vhl-Deficient, Pbrm1-Deficient,
or Vhl and Pbrm1 Doubly Deficient
Mouse Renal Cortices Identifies
Distinct Clusters
To determine why double deficiency of
Vhl and Pbrm1, but not single deficiency
of either gene, resulted in ccRCC, we performed gene expres-
sion profiling of RNA isolated from renal cortices of 12-week-
old WT, VhlF/FKsp-Cre, Pbrm1F/FKsp-Cre, and VhlF/FPbrm1F/F
Ksp-Cre mice. Kidneys from 12-week-old mice were chosen
to avoid potentially confounding transcriptional changes sec-
ondary to cystic anomalies that normally manifest after 6 months
of age. Of note, none of the 12-week-old mouse kidneys dis-
played discernible macroscopic or microscopic cystic abnor-
malities at necropsy regardless of genotypes. Genes differ-
entially expressed in at least one genotype were identified
(Table S2A) and subjected to unsupervised hierarchical
Cell Reports 18, 2893–2906, March 21, 2017 2897
clustering analysis, which revealed three distinct clusters (Fig-
ure 5A). Cluster I showed enrichment of genes that were upre-
gulated in Vhl-deficient renal cortices and further upregulated
in Vhl and Pbrm1 doubly deficient renal cortices. In contrast,
cluster III showed enrichment of genes that were downregu-
lated in Vhl and Pbrm1 doubly deficient renal cortices. Each
cluster was then analyzed and visualized using ClueGO (Bindea
et al., 2009) to interrogate functionally grouped gene ontology
and pathway networks (Figure 5B; Table S2B). Pathways
over-represented that are highly pertinent to known ccRCC
pathogenesis were HIF1 and JAK-STAT pathway genes in clus-
ter I and oxidative phosphorylation (OXPHOS) genes in cluster
III (Figure 5B), whereas no pathway was significantly enriched
in cluster II.
Figure 4. VhlF/FPbrm1F/FKsp-Cre Mice Tu-
mors Are Transplantable and Invasive
(A) Representative gross images (column 1),
histopathological images (column 2), and immu-
nohistochemistry of CA-IX (column 3) of donor
VhlF/FPbrm1F/FKsp-Cre kidney tumors (row 1),
primary allograft kidney tumors (row 2), and sec-
ondary allograft kidney tumors (row 3).
(B) Representative histopathological image (top)
and immunohistochemistry of CA-IX (bottom) of
the transplanted invasive tumors.
(C) PCR genotyping of WT kidney and donor and
allograft VhlF/FPbrm1F/FKsp-Cre tumors.
PBRM1 Loss Amplifies the
Transcriptional Outputs of HIF1 and
STAT3 Incurred by VHL Loss
HIF1a is stabilized upon VHL loss and
plays a central role in the pathogenesis
of ccRCC. It was reported that HIF1
induces PKM2 to activate STAT3, which
in turn induces HIF1a expression (Dema-
ria and Poli, 2012; Luo and Semenza,
2012). Furthermore, it is known that
HIF1 and STAT3 cooperate to activate
the expression of HIF1 targets including
genes involved in angiogenesis (Jung
et al., 2005). Consequently, the intricate
interplay between HIF1 and STAT3 estab-
lishes a feed-forward amplification loop
to maximize target gene expression.
Our discovery that HIF1 and JAK-STAT
pathway genes were enriched in Vhl-defi-
cient renal cortices and further enriched in
Vhl and Pbrm1 doubly deficient renal
cortices raises a hypothesis in which
PBRM1 prevents the amplification of the
HIF1 and STAT3 transcriptional outputs
that are initiated upon VHL loss.
To test this, we identified HIF1 and
STAT3 motifs from differentially ex-
pressed genes to determine the strength
of regulation of the targets by indi-
vidual transcription factor binding motifs
(TFBMs). RNA expression data were analyzed using Integrated
System for Motif Activity Response Analysis (ISMARA) (Balwierz
et al., 2014), which produced an output denoting the inferred
activity of HIF1 and STAT3 motifs in every sample. An increase
in the HIF1 (p = 0.08) and STAT3 (p = 0.017) motif activities
was detected when comparing VhlF/FKsp-Cre to WT kidneys,
and a marked increase in both HIF1 (p = 0.00076) and STAT3
(p = 0.00018) outputs was identified when comparing VhlF/F
Pbrm1F/FKsp-Cre to WT kidneys. In contrast, no changes in
HIF1 (p = 0.49) or STAT3 (p = 0.98) motif activity were observed
when comparing Pbrm1F/FKsp-Cre toWT kidneys. Remarkably,
the effects of Pbrm1 deletion on HIF1 and STAT3 targets mani-
fested only under the premise of Vhl loss, resulting in a further
increase of the HIF1 (p = 0.035) and STAT3 (p = 0.0022) motif
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Figure 5. PBRM1 Loss Amplifies the Transcriptional Outputs of HIF1 and STAT3 Incurred by VHL Loss
(A) Heatmap of genes with significantly different expression in the renal cortices of WT, VhlF/FKsp-Cre, Pbrm1F/FKsp-Cre, and VhlF/FPbrm1F/FKsp-Cre mice at
12 weeks of age. Unsupervised hierarchical agglomerative clustering identified three distinct clusters using Pearson correlation and average linkage as similarity
measures for pairs of genes and pairs of inchoate clusters, respectively.
(B) Clusters I and III were tested for pathway enrichment and presented using ClueGO.
(C) Inferred HIF and STAT motif activities across the indicated genotypes. *p = 0.035; **p = 0.0022 (one-sided t test).
(D) The mRNA levels of the indicated genes from the indicated genotypes were assessed by qRT-PCR. Data were normalized against GAPDH (mean ± SD, n = 3
independent experiments). *p < 0.05; **p < 0.005 (Student’s t test).
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activities when comparing VhlF/FPbrm1F/FKsp-Cre to VhlF/FKsp-
Cre kidneys (Figure 5C). To further validate these findings, we
performed qRT-PCR analyses on Hif1a, Stat3, and representa-
tive HIF1 target genes (Pdk1 and Egln3) as well as STAT3 target
genes (Socs3, Il4r, and Il6r) (Figures 5D and S6A–S6D), which
demonstrated consistent results among different gene expres-
sion assays. Of note, we did not see any transcriptional upregu-
lation of HIF2a. In summary, our data suggest that PBRM1, a
SWI/SNF complex protein, could function like a transcriptional
resistor to prevent uncontrolled self-perpetuating amplification
of the HIF1 and STAT3 transcriptional outputs incurred by Vhl
deficiency. To further interrogate this working hypothesis, qRT-
PCR was performed on NIH 3T3 cells with knockout of Vhl,
Pbrm1, or both using CRISPR-Cas9. Indeed, the loss of
PBRM1 further enhances HIF1 and the STAT3 signaling that
was primed upon the loss of VHL (Figure S6G).
The Expression of OXPHOS Genes Is Markedly
Downregulated in Vhl and Pbrm1 Doubly Deficient
Mouse Kidneys
In contrast to cluster I that encompasses upregulated genes in
the VhlF/FPbrm1F/FKsp-Cre kidneys, cluster III mainly consists
of significantly downregulated genes (Figure 5A) within which
most enriched are OXPHOS genes (Figure 5B). The significant
downregulation of nuclear-encoded OXPHOS genes was further
confirmed by qRT-PCR of genes involved in different electron-
transport chain complexes, including Ndufa2 (complex I), Sdhd
(complex II), Cox5a (complex IV), and Atp4a (complex V) (Figures
5D, S6E, and S6F). HOMER analysis was performed to deter-
mine if specific transcription factors might have directly medi-
ated such repression. However, we did not detect enrichment
of any pertinent TFBMs within the cluster III genes. It has been
shown that HIF1 inhibits mitochondrial biogenesis and respira-
tion through downregulation of PGC1b transcription in RCC4,
a VHL-deficient human kidney cancer cell line (Zhang et al.,
2007). However, neither gene expression profiling nor qRT-
PCR detected significant downregulation of Pgc1b in VhlF/F
Pbrm1F/FKsp-Cre kidneys (Figure S6F). TCGA pan-kidney can-
cer analysis on common human kidney cancer types, including
KIRC (kidney renal clear), KIRP (kidney renal papillary), and
KICH (kidney chromophobe), demonstrated a significant down-
regulation of OXPHOS genes in ccRCC, but not in papillary RCC
(pRCC) or chromophobe RCC (chRCC) (Chen et al., 2016).
Vhl and Pbrm1 Doubly Deficient Clear Cell Kidney
Tumors Display Hyperactive mTORC1 Signaling
The observation that clear cell kidney tumors occurred in VhlF/F
Pbrm1F/FKsp-Cre mice after a long latency period suggests the
involvement of additional genetic and/or epigenetic events. To
investigate whether transcriptional aberrations might be respon-
sible, RNA sequencing (RNA-seq) was performed on VhlF/F
Pbrm1F/FKsp-Cre kidney tumors and age-matched WT renal
cortices. The complex pathological changes observed in the
aged VhlF/FPbrm1F/FKsp-Cre mouse kidneys precluded the
isolation of adjacent normal renal cortices for comparison.
Differentially expressed genes were identified (Table S3)
and subjected to unsupervised hierarchical clustering anal-
ysis, which identified two clusters denoting tumors and normal
controls (Figure 6A). These genes were analyzed and visualized
with ClueGO to interrogate functionally grouped gene ontology
and pathway networks (Figure 6B; Table S4). Gene Set Enrich-
ment Analysis (GSEA) revealed upregulation of HIF1 and
STAT3 pathways and downregulation of OXPHOS pathway in
VhlF/FPbrm1F/FKsp-Cre tumors (Figure 6C), consistent with the
findings observed in the 12-week-old VhlF/FPbrm1F/FKsp-Cre
renal cortices (Figure 5B). Significantly, dysregulation of the
mTOR signaling pathway was shown in the Vhl and Pbrm1
doubly deficient tumors but not in the 12-week-old VhlF/F
Pbrm1F/FKsp-Cre renal cortices (Figures 5B, 6B, and 6C;
Table S4). To validate RNA-sequencing findings, qRT-PCR
focused on the HIF1 and mTOR pathway genes was performed
(Figures 6E and 6F), which demonstrated consistent findings
among gene expression analysis platforms. We also performed
immunohistochemistry on VhlF/FPbrm1F/FKsp-Cre mouse tu-
mors to assess HIF1 and mTOR signaling. A significant nuclear
accumulation of HIF1, a weak nuclear accumulation of HIF2,
and an expression of GLUT1, an HIF target, were detected in
these tumors (Figure S7A). Furthermore, increased phosphoryla-
tion of 4E-BP1 and S6K, two well-established mTORC1 sub-
strates, were detected in VhlF/FPbrm1F/FKsp-Cre tumors but
not adjacent normal-looking kidney tissues (Figures 6D and
S7B). In contrast, the phosphorylation of ERK was not increased
in the Vhl and Pbrm1 doubly deficient kidney tumors (Figure 6D).
It is noteworthy that Ddit4 or Redd1, a transcriptional target of
HIF1 (Brugarolas et al., 2004), was significantly upregulated in
Vhl and Pbrm1 doubly deficient kidney tumors (Figure 6E).
REDD1 is known to suppress mTORC1 activity by releasing
TSC2 from its inhibitor 14-3-3 (Brugarolas et al., 2004; DeYoung
et al., 2008). Several lines of clinical evidence support the impor-
tance of mTORC1 activation in the pathobiology of human
ccRCC, including the known therapeutic benefit of administering
mTORC1 inhibitors in treating metastatic ccRCC (Voss et al.,
2014; Wei and Hsieh, 2015) and the observed prevalent
mTORC1 pathway activation in human ccRCC (Linehan et al.,
2010; Robb et al., 2007). Induction of REDD1 by HIF1 may acti-
vate a tumor suppressor checkpoint that restrains the oncogenic
potential of HIF1. Hence, activation of mTORC1 activity through
additional genetic/epigenetic events may be required for the
initiation of ccRCC in Vhl and Pbrm1 doubly deficient renal
epithelial cells. In fact, significant downregulation of Tsc1 and
Tsc2 was demonstrated in Vhl and Pbrm1 doubly deficient
kidney tumors (Figure 6F), which would activate mTORC1
even when REDD1 was upregulated. In summary, the emergent
mTORC1 activation detected in the Vhl and Pbrm1 doubly defi-
cient ccRCC may represent a prerequisite oncogenic driver
event in the pathogenesis of ccRCC once kidney epithelial cells
lost VHL and PBRM1.
Analyses of Mouse and Human ccRCC Reveal
Convergence on the mTOR Pathway Activation
Contrary to the inability of Vhl deficiency to initiate ccRCC in
mice, the Hif1a-M3 transgenic model (Hif1a-M3 TRACK) where
kidney-specific overexpression of a non-degradable as well
as transcriptionally active mutant HIF1a-M3 (P402A, F564A,
N803A) resulted in renal cysts and small clear cell tumors in
aged (14–22 months) mice (Fu et al., 2011, 2015). Of note,
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Figure 6. Vhl and Pbrm1 Doubly Deficient Clear Cell Kidney Tumors Display Hyperactive mTORC1 Signaling
(A) Heatmap of genes with significantly different expression in age-matchedWT kidneys (n = 4) and VhlF/FPbrm1F/FKsp-Cre tumors (n = 5) based on unsupervised
hierarchical agglomerative clustering.
(B) The genes that were significantly, differentially expressed in VhlF/FPbrm1F/FKsp-Cre T/N (false discovery rate [FDR] <0.05) were tested for enrichment and
represented using ClueGO.
(C) GSEA plots of the ranked list of differentially expressed genes in VhlF/FPbrm1F/FKsp-Cre kidney tumors (T) and WT normal kidneys (N) generated using three
gene sets: curated HIF targets, KEGG JAK STAT signaling pathway, KEGG oxidative phosphorylation pathway, and KEGG mTOR Pathway enrichment.
(D) Immunohistochemistry of phosphorylated-4E-BP1 (p4E-BP1) at threonine 37/46 (column 1), phosphorylated S6K (pS6K) at serine 240/244 (column 2), and
phosphorylated ERK1/2 (pERK) at threonine 202/tyrosine 204 in VhlF/FPbrm1F/FKsp-Cre tumors. T, tumor; N, adjacent normal. Scale bars are at 100 mmor 200 mm
as indicated.
(E and F) The mRNA levels of Ddit4 (E, top left), Ldha (E, top right), Hk2 (E, bottom left), Glut1 (E, bottom right), Tsc1 (F, left), and Tsc2 (F, right) in VhlF/F
Pbrm1F/FKsp-Cre tumors (n = 6) and WT kidneys (n = 4) were assessed by qRT-PCR. Data were normalized against GAPDH (mean ± SD). *p < 0.05; **p < 0.005;
***p < 0.0005 (Student’s t test).
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oxygen-dependent hydroxylation of P402 and F564 of HIF1a
by prolyl hydroxylase domain enzymes (PHDs) and of N803 by
factor inhibiting HIF (FIH) enhances the HIF-VHL interaction,
leading to its degradation (Keith et al., 2011; Masson and Rat-
cliffe, 2014). Furthermore, hydroxylation of N803 by FIH also
disrupts the interaction between HIF and transcription coac-
tivator p300/CBP, thereby inhibiting HIF1-mediated transcrip-
tion (Masson and Ratcliffe, 2014). Although VHL loss leads to
the stabilization of HIF1a and HIF2a, oxygen-dependent and
FIH1-mediated asparaginyl hydroxylation of HIFs prevents the
recruitment of p300/CBP, which helps explain why Vhl defi-
ciency alone is insufficient for kidney tumor initiation.
To further determine whether mTORC1 activation might be
a mechanistically preferred node after the hyperactivation of
HIF1 during the pathogenesis of ccRCC, we resorted to the
transcriptomic data of the Hif1a-M3 TRACK mouse model.
Indeed, GSEA revealed upregulation of the mTOR signaling
pathway (Figure 7A). As expected, upregulation of HIF1 and
JAK/STAT signaling pathways and downregulation of the
OXPHOS pathway were also seen in the Hif1a-M3 TRACK
mouse model (Figure 7A). We further compared the transcrip-
tomics of the VhlF/FPbrm1F/FKsp-Cre tumors to those of the
Hif1a-M3 TRACK mouse model (Figure 7B). Within the 2,430
differentially expressed genes shared between these two
models, enrichment in the mTOR and HIF1 pathways was
evident (Figures 7B and 7C; Table S5). The shared mTOR
pathway aberration between these two different mouse ccRCC
models supports the convergence on mTORC1 activation once
HIF1 becomes hyperactive (Figures 7A–7C).
To determine whether this observation could be extended into
human ccRCC bearing both VHL and PBRM1mutations, we first
compiled differentially expressed genes in human VHL- and
PBRM1-mutated ccRCC from the TCGA-KIRC dataset. Consis-
tent with the findings observed in mouse ccRCC, GSEA of these
differentially expressed genes revealed upregulation of HIF1,
JAK/STAT3, and mTOR pathways and the downregulation of
OXPHOS pathway (Figure 7D). Next, we compared the differen-
tially expressed genes identified in human VHL- and PBRM1-
mutated ccRCC to those shared between the two mouse
models, which resulted in the identification of 1,772 genes that
were shared among these three ccRCC models (Figure 7B).
Within this shared gene set, HIF1 and mTOR pathway genes
were statistically enriched again (Figure 7E; Table S6). Taken
together, our study favors a scenario in which a sequence
of at least three distinct genetic/epigenetic events including
the loss of VHL, the loss of PBRM1, and the subsequent activa-
tion of mTORC1 are required for the development of ccRCC
(Figure 7F).
DISCUSSION
VHL is the most commonly mutated gene in human ccRCC and
its mutation serves as the initial driver event in the pathogenesis
of ccRCC (Linehan et al., 1995). However, genetic deletion of Vhl
in mice is insufficient to initiate kidney tumors (Haase et al.,
2001; Kapitsinou and Haase, 2008), favoring the involvement
of additional genetic/epigenetic events. Such events remained
elusive till the discovery of additional 3p21 tumor suppressor
genes commonly mutated in human ccRCC, i.e., PBRM1,
SETD2, and BAP1 (Hakimi et al., 2013b). Although PBRM1 is
the second most commonly mutated gene in human ccRCC,
whether and how PBRM1 loss contributes to the pathogenesis
of ccRCC are unknown. Through tissue-specific deletion of
both Vhl and Pbrm1 (VhlF/FPbrm1F/FKsp-Cre), we created a clear
cell kidney cancer mouse model that recapitulates histopatho-
logical and molecular features of human ccRCC and elucidated
how PBRM1 functions as a tumor suppressor in ccRCC.
The VhlF/FPbrm1F/FKsp-Cre mice developed preneoplastic
polycystic kidney lesions at 6 months and multifocal ccRCC
at 10 months, suggesting that loss of Vhl and Pbrm1 in kidney
predisposes to ccRCC. The human pan-cancer genomics iden-
tified SWI/SNF complexes as commonly mutated genes (20%)
across cancer types with preferential enrichment of individual
mutations in specific cancer types (Helming et al., 2014; Kadoch
et al., 2013; Marquez et al., 2015), which presents challenges
and opportunities in broadening our knowledge on how chro-
matin remodeling ATPase complexes function as tumor sup-
pressors. Among the SWI/SNF complexes, SMARCB1 (BAF47)
is the best-characterized tumor suppressor that regulates cell
cycle and antagonizes PRC2 complex (Helming et al., 2014).
Expression profiling of 12-week-old VhlF/FPbrm1F/FKsp-Cre
renal cortices revealed the tumor suppressor role of PBRM1 in
preventing the self-perpetuating over-amplification of the HIF1
pathway through limiting the intricate feed-forward interplay
between HIF1 and STAT3 upon VHL loss (Demaria and Poli,
2012; Jung et al., 2005; Luo and Semenza, 2012). The unex-
pected tumor suppressor function of PBRM1 is analogous to
an electrical resistor in preventing power overdrive, in which
PBRM1 restrains the HIF1 and STAT3 transcription outputs
from over-amplification upon the loss of VHL (Figure 7F).
The observation that clear cell kidney tumors occurred
in VhlF/FPbrm1F/FKsp-Cre mice after a long latency period
Figure 7. Analyses of Mouse and Human ccRCC Reveal Convergence on the mTOR Pathway Activation
(A) GSEA plots of the ranked list of differentially expressed genes in Hif1a-M3 TRACK mouse tumors (T) and normal (N) generated using four gene sets: curated
HIF targets, KEGG JAK STAT signaling pathway, KEGG oxidative phosphorylation pathway, and KEGG mTOR Pathway.
(B) Venn diagram of differentially expressed genes in VhlF/FPbrm1F/FKsp-Cre tumors (T) versus WT normal (N) (T/N), Hif1a-M3 TRACK T/N samples, and human
VHLmtPBRM1mt ccRCC tumors versus normal.
(C) The differentially expressed genes at the intersect of VhlF/FPbrm1F/FKsp-Cre T/N and Hif1a-M3 TRACK T/N were tested for enrichment and presented using
ClueGO.
(D) GSEAplots of the ranked list of differentially expressed genes in human VHLmtPBRM1mt ccRCC tumors versus normal kidneys generated using four gene sets:
curated HIF targets, KEGG JAK STAT signaling pathway, KEGG oxidative phosphorylation pathway, and KEGG mTOR Pathway.
(E) The shared differentially expressed genes in VhlF/FPbrm1F/FKsp-Cre T/N, Hif1a-M3 TRACK T/N, and TCGA-KIRC VHLmtPBRM1mt T/N were tested for
enrichment and presented using ClueGO.
(F) Model depicts the chronological sequences of genetic and signaling events during the pathogenesis of Vhl and Pbrm1 doubly deficient ccRCC.
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suggests the involvement of additional signaling aberrations.
Immunohistochemical and transcriptomic analyses demon-
strated that activation of mTORC1 rather than the ERK pathway
is the preferred third event. Ample evidences support the impor-
tance of mTORC1 activation in the pathobiology of human
ccRCC, e.g., mTORC1 pathway activation is prevalent in human
ccRCC (Linehan et al., 2010; Robb et al., 2007) and mTOR inhib-
itors are standard of care in treating metastatic ccRCC (Voss
et al., 2014; Wei and Hsieh, 2015). As REDD1, a key transcrip-
tional target of HIF1, negatively regulates mTORC1 through
activation of TSC1/TSC2 (Brugarolas et al., 2004; DeYoung
et al., 2008), it is foreseeable that mTORC1 activation could
be a bottleneck for tumors originating from a hyperactive HIF1
signaling. Consistent with this working hypothesis, both the
VhlF/FPbrm1F/FKsp-Cre and the published HIF1a-M3 TRACK
mouse models (Fu et al., 2011) developed ccRCC after a long
latency period and showed convergence on mTORC1 activa-
tion (Figure 7F). Moreover, mTORC1 pathway activation was
also observed in human ccRCC carrying mutations of VHL and
PBRM1 (Figure 6E). Of note, multi-regional sequencing of a
hereditary VHL syndrome patient also detected the mutations
of PBRM1 and the convergence of mTORC1 pathway activa-
tion (Fisher et al., 2014). These findings are consistent with
a recurrent oncogenic theme in which many oncogenes, such
as c-MYC, BRAF, and MLL-fusions, activate both oncogenic
signaling and intrinsic tumor-suppressor checkpoints (Liu
et al., 2014; Lowe et al., 2004; Maertens et al., 2013). Therefore,
abrogating the built-in intrinsic tumor suppressor activities of in-
dividual oncogenes is essential for tumorigenesis. It was recently
reported that homozygous deletion of Vhl and Bap1 in mouse
kidney resulted in early lethality (<1 month), and some mice
(within a cohort of 7) carrying homozygous deletion of Vhl and
heterozygous deletion of Bap1 developed tumor micronodules
(0.25–1.8 mm) with unknown tumor incidence, transplantability,
and molecular characteristics (Wang et al., 2014). Notably, com-
plete BAP1 inactivation is observed in human ccRCC (Pen˜a-
Llopis et al., 2012). How heterozygous loss of Bap1 cooperates
with Vhl loss to initiate kidney tumorigenesis in mice remains
intriguing (Wang et al., 2014).
The suppression of OXPHOS genes observed in the VhlF/F
Pbrm1F/FKsp-Cre ccRCC model is consistent with the global
metabolomics reported on ccRCC (Hakimi et al., 2016), which
lends further support for the notion that kidney cancer is a
metabolic disease that manifests with massive metabolic re-
programming (Hakimi et al., 2016; Linehan et al., 2010). Inhibitors
of mTORC1, the key cellular complex integrating nutrient and
growth factor signaling to promote anabolic metabolism, are
standard of care for metastatic ccRCC (Voss and Hsieh, 2016).
However, a wide range of clinical outcomes has been observed.
Interestingly, genomic study of RECORD-3, a large clinical trial
that randomized kidney cancer patients to either VEGFR or
mTORC1 inhibitors, demonstrated that ccRCC with mutant
PBRM1 associates with longer progression free survival (PFS)
on everolimus, an mTORC1 inhibitor, at 12.8 months than
those with wild-type PBRM1 at 5.5 months (Hsieh et al., 2015,
2017a). In parallel, the VhlF/FPbrm1F/FKsp-Cre ccRCC and hu-
man VHL- and PBRM1-mutated ccRCC shared mTORC1
pathway aberration. Both clinical data and this study support a
model in which mTORC1 activation constitutes the preferred
third driver event during ccRCC tumorigenesis immediately after
genetic inactivation of VHL and PBRM1 (Voss and Hsieh, 2016)
(Figure 7F), which serves as an example of preferential pathway
convergent evolution of a given cancer type (Voss and Hsieh,
2016; Wei and Hsieh, 2015) that could have predictive values
for selecting patients of a given cancer genotype with matched
targeted therapies.
EXPERIMENTAL PROCEDURES
More detailed information is available in the Supplemental Experimental
Procedures.
Mice
Baf180F/F mice were obtained from Dr. Wang Zhong (Wurster et al., 2012).
Animal experiments were performed in accordance to the Institutional Animal
Care and Use Committee (IACUC) at MSKCC.
Mouse MRI
Mice MRI scans were carried out on either 200 or 300 MHz Bruker 4.7 T or
7 T Biospec scanners (Bruker Biospin MRI GmbH) equipped with 640 mT/m
ID 115 mm and 300 mT/m ID 200 mm gradients, respectively (Resonance
Research).
RNA Isolation and Microarray Analysis
Total RNA was isolated using TRIzol (Life Technologies) and cleaned up using
QIAGEN column DNase digestion. RNA samples were prepared from
3-month-old Ksp-Cre, VhlF/FKsp-Cre, Pbrm1F/FKsp-Cre, and VhlF/FPbrm1F/F
Ksp-Cre mice. Microarray was performed by Integrated Genomics Operation
(IGO) at MSKCC.
RNA-Seq and Analysis
Total RNAwas process by the IGO using TruSeq RNASample Prep kit accord-
ing to the manufacturer’s recommendation. Gene ontology (GO) analysis of
mouse microarray and RNA-seq data were performed with ClueGO.
Motif Activity Analysis
To analyze activities of transcription factor binding motifs (TFBM) using RNA-
seq data, we used the Integrated System for Motif Activity Response Analysis
(ISMARA).
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